Core Insights - PTC Therapeutics reported significant growth in revenue driven by the launch of Sephience for phenylketonuria (PKU), achieving $92 million in the fourth quarter and $111 million since its launch in 2025 [1][4][7] - The company exceeded its revenue guidance for 2025, reporting total net product and royalty revenue of $831 million, up from the previous guidance of $750 million to $800 million [2][6] Financial Performance - For Q4 2025, PTC's total net product and royalty revenue was $263 million, contributing to a full-year total of $831 million [2][4] - The company ended 2025 with $1.95 billion in cash, following the monetization of Evrysdi royalties for $240 million upfront [6][22][23] - PTC guided for 2026 product revenue between $700 million and $800 million, indicating a growth of 19% to 36% compared to 2025 [24] Product Development and Approvals - Sephience received approvals in the U.S., E.U., and Japan, with early commercial momentum noted through broad uptake across various patient demographics [3][7][8] - The company plans to expand Sephience's commercial footprint internationally, targeting 20 to 30 countries by the end of 2026 [11][13] Market Dynamics - Payers have shown favorable early reimbursement for Sephience, with minimal barriers to access and long refill periods [9][10] - The company is addressing the needs of "lost to follow-up" adults, leveraging social media and community networks to re-engage patients [10] Pipeline Updates - PTC is advancing its pipeline with Votoplam for Huntington's disease, with a phase III trial expected to start in H1 2026 [5][18] - For Vatiquinone, an additional study is required for NDA resubmission, with plans to align on the protocol with the FDA [19] Other Revenue Streams - The Duchenne muscular dystrophy (DMD) franchise contributed $66 million in Q4, with Evrysdi royalties generating $79 million [14][15] - The company continues to face challenges in the DMD market due to increased generic competition [15]

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide as of December 31, 2025 [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [8][15] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential multi-billion dollar global revenue opportunity for Sephience, citing its differentiated profile and broad uptake [8][12] - The company anticipates reaching cash flow break-even in 2026, a significant milestone [7][20] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [19] - The FDA has requested an additional study for Vatiquinone, which the company plans to pursue [39] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and contributions from mature products [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Many adults previously lost to follow-up are now seeking therapy due to social media awareness and positive patient experiences shared online [30][31] Question: What are the dynamics for Vatiquinone's additional study? - The FDA suggested an open-label or single-arm study with a natural history comparator group, which the company plans to discuss further [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, indicating strong early adoption [46][47] Question: How will Sephience's growth in Europe be affected after the free pricing period? - The company anticipates maintaining a strong price based on the clinical data package and ongoing negotiations [51][53]

Financial Data and Key Metrics Changes - The company reported a strong start for Sephience, its oral therapy for PKU, with continued momentum into the fourth quarter, indicating a path to cash flow break-even and beyond [3][6][48] - The average time from patient support form (PSF) to getting on the drug is currently two to four weeks, reflecting efficient execution in the launch process [7][8] Business Line Data and Key Metrics Changes - Sephience has seen early success with 341 patients on therapy, indicating a significant opportunity in the PKU market, which has about 17,000 patients in the U.S. [4][5] - The company has experienced uptake across all patient segments, including switches from existing therapies and therapy-naive patients, demonstrating broad market penetration potential [14][15][16] Market Data and Key Metrics Changes - The company is preparing for global launches in Europe, Japan, and Brazil, with infrastructure and teams ready to navigate local regulatory environments [21][22][25] - In Europe, the company is leveraging its experience with Translarna to maintain a significant market presence despite the lack of formal approval for Sephience [65][66] Company Strategy and Development Direction - The primary focus remains on the successful launch of Sephience, while also advancing a robust R&D pipeline, including small molecule splicing programs [42][45] - The company is exploring strategic partnerships to leverage its RNA platform for future therapies, particularly in oncology and neurodegenerative diseases [45][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for Sephience, supported by compelling patient stories and positive feedback from the prescriber community [6][20] - The company is committed to managing expenses and achieving cash flow break-even, with plans to reduce operating expenses in 2026 relative to 2025 [48] Other Important Information - The company is actively engaging with regulatory bodies regarding the potential for accelerated approval pathways for its Huntington's disease program, Votoplam, highlighting its differentiated approach compared to gene therapies [54][56] - The company is also addressing the implications of the Most Favored Nation (MFN) rule and its impact on pricing strategies [51] Q&A Session Summary Question: What are the adoption patterns for Sephience across different patient segments? - The company is seeing uptake across all segments, including switches from Kuvan and therapy-naive patients, indicating a broad market opportunity [14][15] Question: How is the company preparing for global launches? - The company has infrastructure and teams ready for launches in Europe, Japan, and Brazil, with careful planning around pricing and reimbursement negotiations [21][22][25] Question: What is the company's strategy for managing expenses? - The company is focused on achieving cash flow break-even and plans to reduce operating expenses in 2026, while balancing internal development and partnerships [48]

Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on rare diseases, with a portfolio that includes six self-marketed products worldwide [4] - The company has a robust R&D pipeline, highlighted by its small molecule splicing platform, which has produced Evrysdi for spinal muscular atrophy (SMA) and Votoplam for Huntington's disease [4] Financial Performance - For the third quarter, PTC Therapeutics reported strong performance with revenues of $211 million, which included contributions from Sephience, their phenylketonuria (PKU) drug [5] - The company maintains a strong financial position with approximately $1.7 billion on its balance sheet [5] Product Launch - The launch of Sephience is a significant event for the company, providing a foundation for future growth [5]

Financial Performance and Goals - PTC aims for a \$2 billion topline revenue through commercial launches and innovative R&D platforms[9],[48] - The company is focused on reaching cash flow breakeven without additional capital[11],[48] Sephience (Sepiapterin) for PKU - Sephience global launch has generated \$19.6 million in revenue, including \$14.4 million in the US and \$5.2 million ex-US[16] - 341 patients are on commercial Sephience therapy worldwide[16] - Sephience treatment resulted in a 63% mean blood Phe reduction in the overall primary analysis population compared to a 1% reduction with placebo (p<0.0001)[18] - In classical PKU patients, Sephience treatment resulted in a 69% mean blood Phe reduction compared to a 3% reduction with placebo (p<0.001)[18] - Sephience showed a 70.3% greater reduction in blood Phe concentration compared to sapropterin (BH4) (p < 0.0001)[24] Votoplam for Huntington's Disease - Novartis will provide a \$1 billion upfront payment for the votoplam collaboration[35] - PTC could receive up to \$1.9 billion in development, regulatory, and sales milestones from Novartis[35] - PTC will receive a 40% U S profit share and double-digit tiered royalties on ex-U S sales from Novartis[35] Vatiquinone for Friedreich's Ataxia - Vatiquinone demonstrated a 42% slowing (p=0.021) of disease progression in the Upright Stability score over 72 weeks compared to placebo[39] - Long-term extension studies showed a 50% slowing (p<0.0001) of disease progression over 3 years[40] - A 4.8-point benefit (p<0.0001) on mFARS over 2 years in ambulatory and non-ambulatory adults was observed[40]